MLL Münchner Leukämielabor GmbH

Industry / private company


Location: München, Germany (DE) DE

ISNI: 0000000475538497

ROR: https://ror.org/00smdp487

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV (2014) Kalmanti L, Saussele S, Lauseker M, Proetel U, Mueller MC, Hanfstein B, Schreiber A, et al. Journal article Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV (2014) Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, et al. Journal article Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib (2014) Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, et al. Journal article
‹ 1 2 3 ›